Alizé Pharma SAS holds a strong IP position on the AZP-01 project, which consists of 4 families of patents applications related to unacylated ghrelin, its analogs and their potential clinical indications, and filed internationally. Among these patents applications, a first one was recently granted in the US (U.S. 7,485,620)

As for the ASPAREC® program (AZP-02), Alizé Pharma II SAS has filed a first patent application in 2009, covering the ASPAREC® product and its clinical uses.